secwatch.observer — SEC 8-K summary
======================================

Issuer:     Enliven Therapeutics, Inc. (ELVN)
CIK:        0001672619
Form:       8-K
Filed at:   2024-11-13T23:59:59+00:00
Accession:  0000950170-24-126323
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Enliven Q3 net loss $23.2M; ELVN-001 Phase 1 MMR rate 44% by 24 weeks
---------------------------------------------------------------------

- Cash $291.8M as of Sept 30, 2024; runway into late 2026.
- Net loss $23.2M (Q3 2024) vs $20.8M (Q3 2023); R&D expenses $21.3M.
- ELVN-001 Phase 1: cumulative MMR 44% (8/18) by 24 weeks; no dose reductions at ≥40 mg due to TRAEs.
- Plan to report additional ELVN-001 data in 2025 with ~60-100 patients across lines of therapy.
- ELVN-002 trials in HER2+ MBC and CRC ongoing; data anticipated in 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1672619/000095017024126323/0000950170-24-126323-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1672619/000095017024126323/elvn-20241113.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-126323

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer